Healthcare Stock Bulls XOMA AXN PGNX

Today has been a very big day for a select few in biotech. Here are today’s most bullish biotech stocks and what we can expect to see moving forward…

Aoxing Pharmaceutical Company Stock Is Today’s Biggest Gainer In Healthcare

Aoxing Pharmaceutical Company Inc (NYSEMKT: AXN)

Aoxing Pharmaceutical Company stock is climbing in the market today; currently (2:53) trading at $2.16 per share after a massive gain of 20.00% so far today. AXN has been the topic of quite the debate after a massive climb between June 5th and June 8th led to a massive reversal; with the stock trading low since. However, it seems like AXN is finally reaching support; and based on today’s growth, I think it may last for at least a couple of days as the stock didn’t simply shoot up, but we’ve seen steady gains all day. With that said, if you’re in for nice short term gains, this may be one that’s well worth looking into.

Progenics Pharmaceuticals Stock Climbs On High Volume

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)

Progenix Pharmaceuticals stock is doing incredibly well in the market today; climbing on incredibly high volume. According to NASDAQ, the average daily volume on PGNX over the past 50 days has been 969,771. However, the volume is far above average today with 4,442,644 shares trading hands so far. As a result, the stock is climbing in a big way. Currently (3:02), PGNX is trading at $8.12 per share after a gain of 11.69% so far today. While we are seeing a slight dip as the trading session comes to a close, based on the bullish trend we’ve seen from PGNX over the past month, I could imagine that this dip may be an opportunity to get in on the action.

XOMA Corp Stock Is Up On High Volume As Well


XOMA Corp is also having a great day thanks to overwhelmingly high trading volume. According to NASDAQ, the average daily volume on XOMA throughout the past 50 days has been 2,127,991. However, today, far more shares have traded hands; and the session hasn’t come to a close yet, Currently (3:08), 5,717,148 shares have traded hands so far today; pushing the value of XOMA to $4.23 per share after a gain of 9.02% so far. XOMA has had a bit of a rough time in the market over recent years. So, while this may present a bit of opportunity moving forward, if you decide to trade this one, it’s highly advised that you trade with caution.

Do You Know Of Any Others?

Do you know of any other big gainers in healthcare today? If so, let us know in the comments below!

Image Credit

MannKind MNKD Stock News Bull

MannKind Corporation (NASDAQ: MNKD)

MannKind has been the talk of the town in the healthcare sector for quite some time. It’s pretty rare when a stock stays in the top ten on the healthcare heat map on Stock Twits for more than a month; but MannKind has been there for about three months now. There’s good reason for the strong debate revolving around the stock. Today, we’ll take a look at MNKD from the bearish point of view and the bullish point of view; and we’ll talk about why I’m expecting to see big long term gains from the stock.

MannKind Bearish Argument

The bearish argument on MNKD revolves around Afrezza; the company’s inhaled insulin. As Goldman Sachs pointed out early in pre-launch, sales of Afrezza just haven’t been what analysts expected to see. As a result, the stock was downgraded by Goldman Sachs months ago; causing declines that would last for some time. So, the bearish argument is simple…MannKind’s flagship product is Afrezza, and if Afrezza doesn’t generate sales, investors can’t expect to see profits. However, I think the bears are missing a few key aspects associated with the stock.

MannKind Bullish Argument

Before I get into this side of the argument, I think it’s important to point out that I am a MannKind bull. Personally, I can’t imagine a scenario where MNKD isn’t likely to grow in the long run. There are several reasons for my opinion on this; including the following…

  • Afrezza Is Incredible – First off, we can’t discount the incredible innovation in medicine that Afrezza represents. MannKind has figured out a way to take a medication that was only able to be delivered through an injection and find a way to deliver it through an inhaler. As a guy who is deathly afraid of needles, this is a huge deal for me. However, outside of my own fears, I think this will prove to be a major hit for the diabetic community entirely. The truth is that I have several friends and family members that suffer from diabetes; and after talking to all of them, I haven’t had one tell me that they would rather use a needle than an inhaler. Leading us to the next point…
  • Afrezza Is Still In Pre-Launch Mode – Those who are considering investing in MannKind should keep in mind the fact that Afrezza is still in pre-launch mode. There has been absolutely no advertising as of yet. As a matter of fact, after speaking with several people in the diabetic community, I can honestly say that not one of them even knew about Afrezza before I mentioned it. However, this is likely to change very soon. Within the coming weeks, Afrezza will move into the Direct-to-Consumer campaign; enlightening consumers in the diabetic community with regard to their options. When this happens, I’m expecting to see big gains!
  • Technosphere – The technology that MannKind used to turn the injection only insulin into an inhaled powder is called technosphere and is proprietary to MannKind. This technology is going to be a major game changer for the stock moving forward. That’s because MannKind has been very open about the fact that they are working to use this proprietary technology to develop more treatments. So, in the future, we’re likely to see more injection only medications being delivered through an inhaler; and MannKind will take the profits from the innovation.

All in all, keeping the three main factors in mind, it only makes sense that MannKind is likely to grow long term. So, if this stock isn’t yet in your portfolio, you may want to strongly consider adding it!

What Do You Think?

Where do you think MNKD is headed and why? Let us know in the comments below!

Image Credit

CIGNA Corporation CI Stock News

CIGNA Corporation (NYSE: CI)

Last week, CIGNA Corporation stock started to soar after a rival healthcare company, known as Anthem Inc (NYSE: ANTM) attempted to take over the company with a bid of $47.5 billion. However, today, CI declined the offer; sending the stock even higher. So today, we’ll talk about why the offer was declined, what we’ve seen in the market so far as a result, and what we can expect to see from CI moving forward. So, lets get right to it…

CIGNA Corporation Declines Anthem Takeover Bid

As mentioned above, CIGNA Corporation was recently offered $47.5 billion in a takeover offer from Anthem. However, the company has declined. In an announcement, CI stated that the bid offered isn’t in the best interest of shareholders and highlighted antitrust concerns surrounding the idea of an acquisition. Following the announcement, The Street weighed in with a strong review of the company; offering the following…

We rate CIGNA Corp (CI) a Buy. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins.”

How CI Reacted In The Market Today

Following the news that CI had rejected the takeover bid from ANTM, the company’s stock started to climb. Currently (12:04), CI is trading at $164.22 per share after a gain of 5.77% so far today. So, all in all, it’s clear to see that investors are happy with the company’s decision to decline the bid.

What We Can Expect To See Moving Forward

If you follow my work here or elsewhere, you know that I’m not a fan of taking the analysts word for it when it comes to investing decisions. It’s important to do your own research. Nonetheless, in this particular case, I think that The Street hit the nail on the head. The bottom line is that CIGNA is an incredibly strong company with incredibly strong products. They’ve proven their ability to grow revenue and we’ve seen a pretty strong performance from the stock historically. While profit margins are relatively low at the moment, the upside potential on CI stock far outweighs the downside risk in my opinion.

With that being said, it’s important to remember that price movements in the market are a series of overreactions. So, while CI is having a great day today, we’re likely going to see slight declines tomorrow before seeing slow, yet steady growth moving forward. So, in my humble opinion, now is the time to start looking for pull backs as buying signs.

What Do You Think?

Where do you think CI is headed and why? Let us know in the comments below!

Image Credit

Synergy Pharmaceuticals SGYP Is Down but Not Out

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals stock had an incredible week in the market last week. After announcing data revolving around their most recent study, the stock skyrocketed. However today, SGYP seems to be giving up some of the gains we saw last week. Nonetheless, I’m not concerned as I don’t believe these declines will last very long. Today, we’ll talk about why SGYP had such a strong week last week, why the stock is declining today, and what we can expect to see moving forward. So, let’s get right to it…

What Caused SGYP To Climb Last Week

The growth last week was the result of the release of study data from a study looking into Plecanatide; an experimental drug being studied with the hopes of treating constipation. The results of the study were overwhelmingly positive. Not only was plecanatide effective in treating the condition, it also caused diarrhea in only 6% of patients. This proved to be far better than the current leader Linzess; which is known to cause diarrhea in around 16% of patients that use it.

Why Synergy Pharmaceuticals Stock Is Down Today

When it comes to today’s declines, I can understand the concern among investors. Messages on Stock Twits and Twitter conveying concern seem to be all over the place today. However, as I mentioned above, I’m really not worried. As a matter of fact, I look at today’s declines as an opportunity for those who haven’t gotten in on the gains quite yet. The reality is that the growth we saw in Synergy Pharmaceuticals stock last week was incredible, but not sustainable. Any time we see excessive growth like this, we tend to see a slight correction shortly following the growth before the stock leads the way to slow and steady growth. It’s a classic case of overreactions in the market. Nonetheless, I’m expecting to see growth from the stock relatively soon. So, there’s no need to be concerned about what we’re seeing in SGYP today.

What We Can Expect To See Moving Forward

In the case of SGYP I’ve got an overwhelmingly bullish opinion for both the short and long term. Here’s how I see it…

  • Short Term – Declines may continue today and move into tomorrow. However, by the end of the week, I would imagine that SGYP is going to be trending up once again. While investors got excited about the results, that excitement pushed the stock too high, too fast. So, we’re seeing a correction that’s normalizing the stock’s value before growth continues once again. Nonetheless, the growth will continue.
  • Long Term – In the long term, I’m also expecting to see overwhelmingly positive news from Synergy Pharmaceuticals stock. The reality is that Plecanatide is proving to be a successful venture; and will most likely lead to profits. With strong management, a strong product, and a strong core team, it’s hard for me to imagine a situation where we would see long term declines out of SGYP

What Do You Think?

Where do you think SGYP is headed and why? Let us know in the comments below.

Image Credit

Synergy Pharmaceuticals SGYP Will Climb...Don't Worry

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals has had an incredible week in the market this week. After releasing data from their most recent gastrointestinal study, the company’s stock skyrocketed. However, today, the story seems a bit different. SGYP is currently teetering on the line between profit and losses. Nonetheless, I’m not concerned. I think this one will continue to climb. So today, we’ll talk about why I’m not concerned about the activity we’re seeing from SGYP today and what we can expect to see moving forward.

Why Today’s SGYP Activity Isn’t A Concern

This morning, I’ve already received a Skype message from a friend and SGYP investor. He was starting to become a bit concerned because of the activity we’ve seen this morning. However, I have to say, it’s really not concerning at all. One thing that investors have to remember is the fact that price movement in the market is a series of overreactions. So, when positive news comes out, we see overreactions pushing the stock higher than it should be followed by the same pushing the stock lower before we see steady growth. I think that’s exactly what we’ve seen so far today. After the stock more than doubled over the past two days, it’s time for a bit of a correction before more upward movement can happen.

Why Synergy Pharmaceuticals Stock Is Likely To Climb In The Long Run

As I’ve mentioned in previous posts and above, I’m expecting to see great things from Synergy Pharmaceuticals stock in the long run. Here’s why…

  • Study Results – First off, there’s a real reason for the big climbs we’ve seen. It’s not high volume, it’s not investor sentiment, it’s based on strong fundamental data. As mentioned above, SGYP recently released data from its most recent gastrointestinal study. The study revolved around an experimental drug known as Plecanatide that’s designed to help relieve constipation. The study results showed that not only was Plecanatide effective, it resulted diarrhea for only 6% of patients; far better than the 16% we see from the current leader Linzess.
  • Management – One thing that I look at incredibly closely when making long term predictions is the management of the company. After all, take a look at Twitter Inc (NYSE: TWTR); a company with a great product that’s struggling as the result of poor management. However, SGYP and TWTR are far different animals when it comes to management. The management team at SGYP is plan driven; and clearly has goals that they intend to reach. This is incredibly important when looking for a company to invest in for the long run.
  • Talented Team – Finally, we’ve all heard the saying “a chain is only as strong as its weakest link.” When it comes to SGYP, we’re looking at an incredibly strong chain. The company’s team of physicians and scientists is an incredibly talented one; one that will likely help to send this stock skyrocketing in the long run!

What Do You think?

Where do you think SGYP is headed and why? Let us know in the comments below!

Image Credit

KYTH Acquisition

Kythera Biopharmaceuticals Inc (NASDAQ: KYTH)

This article was originally featured on

Keythera Biopharmaceuticals stock is soaring in the market today following an early morning announcement that the company will be acquired. Today, we’ll discuss who will be acquiring KYTH, the details of the deal, how the stock reacted in the market, and what we can expect to see moving forward. So, let’s get right to it.

KYTH Will Be Acquired By AGN

Allergan, Inc. (NYSE: AGN)

In an early morning announcement today, investors learned that Allergan will be acquiring Kythera Biopharmaceuticals. The deal worked out between the companies is valued at about $2.1 billion; which . According to Thomson Reuters, the equity value of the sale comes to about $1.94 billion. Upon the close of the deal, investors will receive 80% of the total purchase price in cash. The other 20% will be provided to investors in shares of Allergan.

As a result of the acquisition, Allergan is likely to gain quite a bit. The company plans to use Kytheral Biopharmaceuticals as a way to expand its cosmetic treatments. Through the acquisition, AGN will gain access to Kybella; which is Kythera’s first and only approved non-surgical treatemnt to reduce fat under the chin. All in all, this deal is proving to be positive for both sides.

How The Market Is Reacting To The News

Although AGN is trading relatively flat today with gains so far of under 1%, that’s not the case for KYTH. When it comes to KYTH, the stock soared in early morning trading and has stayed flat for the rest of the day. Currently (3:25), KYTH is trading at $74.12 per share after a massive gain of 22.07%.

What To Expect Moving Forward

Moving forward, I’m expecting to see great things from Allergan. In this particular case, I don’t think the outlook can be stated better than the commentary that Jim Cramer provided…

We believe this is a genius deal for Allergan, which this week officially changed its name from Actavis. KYTH is known for having the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, a.k.a. \double chin, with its drug kybella. This perfectly complements the Allergan name, which is known for the famous anti-wrinkle injection Botox, as the company now owns the most important piece of human real estate – the face – through its various treatments directed toward the forehead, eyes, mouth and now chin.”

While the acquisition is indeed brilliant, outside of the acquisition, I believe AGN was already bound for more growth. With the famed Botox, AGN was put on the map; and with strong management the company has stayed there. Now, with the acquisition giving them the ability to target yet another area in cosmetics, the company is only going to get stronger. So, if you’re looking for a biotech gem, it may be time to start looking at AGN for pull backs that are likely to lead to incredible profits in the long run.

What Do You Think?

Where do you think AGN is headed moving forward and why? Let us know in the comments below!

Image Creidt

BMRN Closer To Solving Dwarfism

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

BioMarin Pharmaceutical stock is up today after releasing positive results with regard to the Phase 2 proof-of-concept and dose funding study of BMN 111, also known as vosoritide. Today, we’ll take a look at the results to see what investors are so excited about, talk about what we’ve seen in the market so far as a result, and discus what we can expect from BMRN moving forward. So, let’s get right to it.

BioMarin’s BMN Phase 2 Study Results

BMN 111 is an analog of C-type Natriuretic Peptide for the treatment of children with achondroplasia; the most common form of human dwarfism. In the Phase 2 study, 26 children participated. The study demonstrated a favorable safety profile and efficacy at a dose of 15 micrograms per kilogram per day. 10 children in Cohort 3 were treated with the 15 microgram per kilogram per day dose and had an increase of 50% in anualized growth velocity when compared to their prior 6 month natural history baseline growth velocity. Perhaps more importantly, BMN 111 proved to be safe. There were no serious adverse events; with the majority of adverse events reported being mild headache, hypotension, back pain and cough. Here’s what Wolfgang Dummer, M.D., Ph.D., Vice President of Clinical Development of BMRN had to say…

We are very encouraged to have observed evidence of activity with vosoritide in children participating in our Phase 2 study…In children receiving the highest dose of 15 micrograms per kilogram daily, we observed a 50% increase in mean annualized growth velocity compared to their own natural history control growth velocity. This increase in growth velocity, if maintained, could allow children with achondroplasia to resume a normalized growth rate…More importantly, vosoritide was well tolerated in all dose cohorts and we have observed no major safety concerns to date. Based on these results, we intend to move into pivotal registration study discussions with health authorities with a does of 15 micrograms per kilogram daily. In addition, to support further exploration of a dose that may enable “catch-up” growth in the event of delayed treatment, we intend to study 30 micrograms per kilogram daily in ancillary studies. The next step in our development plan is to review this Phase 2 data with health authorities and our outside advisors to deelop our path forward with registration enabling studies.”

How BMRN Reacted In The Market

As we’ve come to expect any time positive study results are released, BMRN is having a great day in the market today. Currently (12:01), BioMarin Pharmaceutical stock is trading at $139.32 per share after a gain of 12.72% so far today.

What We Can Expect From BMRN Moving Forward

Moving forward, I’m expecting to see a continuation of the bullish activity we’ve seen today. The reality is that in the short term, investor excitement revolving around the result of the study is likely to continue the upward movement. So, looking for dips to take advantage of the climb may be advantageous. In the long run, I’m also expecting bullish activity from BMRN. The vosoritide treatment is proving to be not only effective, but safe; so, I’d imagine approval will come down the road. Also, with a clear plan, strong management, and a strong team, I’m expecting to see continued growth from the stock.

What Do You Think?

Where do you think BMRN is headed and why? Let us know in the comments below!

Image Credit

MannKind and Sanofi Direct To Consumer Campaign

MannKind Corporation (NASDAQ: MNKD) | Sanofi SA (ADR) (NYSE: SNY)

If you follow my writing here or elsewhere, you know that MannKind stock is one of my favorite topics. The company developed an inhaled insulin called Afrezza that I have high hopes for; and that’s where Sanofi comes in. When it comes to Afrezza, it’s Sanofi’s job to get sales really rolling. While things moved very slow in the pre-launch, a big move is coming that could send MannKind and Sanofi stocks soaring!

A Big Afrezza Campaign Is Just Around The Corner

It has been 5 months since the soft launch of Afrezza by Sanofi, and we haven’t seen any massive sales numbers quite yet. However, that’s likely to change relatively soon. Sanofi is known for its marketing ability when it comes to medications; and within the next “several weeks” the company will be launching a Direct-to-Consumers campaign. Although we’ve heard arguments that Afrezza sales have been incredibly low, it’s important to realize what a pre-launch really is and what marketing really is; especially now as marketing is just weeks down the road.

There have been several experts that focused on sales numbers when talking about Afrezza lately. However, in pre-launch, sales isn’t the top priority. Instead, in the pre-launch phase, Sanofi hoped to learn more about the overall sentiment revolving around the drug. The company has talked to endocrinologists in an attempt to educate them on the benefits of Afrezza. They’ve also taken the time to speak to physicians at the American Diabetes Association to provide even more education on the drug. Now that physicians know about it, it’s almost time to move to the Direct-to-Consumer campaign; which will be all about sales. This is a big step that MNKD and SNY investors have been waiting for as the main focus, unlike the pre-launch, will be getting Afrezza sold!

Why I Think MannKind’s Afrezza Will Be Incredibly Profitable

I’ve talked about this a bit in the past. The bottom line is that I’m a huge fan of Afrezza. The inhaled insulin takes the need of needles away from those who are used to injecting their insulin. This is a major step and will most likely be incredibly appealing to the diabetic community. Although Sanofi hasn’t shown much through the pre-launch, it’s also important to remember that the company specializes in sales; and if the past is any indication, they will likely turn Afrezza into an incredibly profitable proposition.

MNKD Outside Of Afrezza

While I’m expecting that Afrezza sales will pick up and MannKind stock will see a nice spike as a result, it’s important to remember that MannKind is going far further than Afrezza. The technology used to turn insulin into an inhaled product, technosphere, is being tested in other indications at the moment. That means that down the road, we’re likely to see MannKind come out with more and more inhaled medications that were once only available through injections. So, while I do believe Afrezza will be incredibly profitable, we can’t discount the profitability in the MNKD proprietary technosphere technology. All in all, Afrezza is likely to drive sales; from there, technosphere is likely to open the door to several more opportunities. So, I’m expecting big things from MNKD.

What Do You Think?

Are you excited about Sanofi’s direct to consumer campaign? What are you expecting to see from MNKD and SNY moving forward? Let us know in the comments below!

Image Credit

SGYP Continues To Climb

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals climbed nicely following the release of information regarding a recent gastrointestinal study. Following the release of the data, the stock climbed in a big way yesterday, and today, it looks like the climb is continuing. So below, we’ll discuss the results of the study that have investors so excited, what we’ve seen in the market so far as a result, and what we can expect to see from SGYP moving forward. So, let’s get right to it…

SGYP Releases Positive Gastrointestinal Results

Wednesday morning, Synergy Pharmaceuticals provided the results of a gastrointestinal study that focused on the effectiveness of placenatide at a 3 milligram dose for the treatment of constipation. The results that were released were incredibly positive; showing that less than 6% of patients that were given placenatide through the study experienced diarrhea as a side effect. This figure came in lower than analysts expected and beat Linzess; which causes about 16% of patients to experience diarrhea.

How Synergy Pharmaceuticals Stock Reacted To The News

As we can expect any time positive news comes out about a biotech company, SGYP had a great day in the market yesterday; gaining well over 50% in a single day. Now, it seems like the climb isn’t over quite yet as excited investors continue to push the stock higher and higher. Currently (10:57), Synergy Pharmaceuticals is trading at $8.28 per share after a gain of 6.43% so far today and is showing no signs of a coming reversal.

What We Can Expect From SGYP Moving Forward

Moving forward, I’m expecting to see more bullish activity out of the stock, both in the short and long term outlooks. Here’s what I see happening moving forward.

  • Short Term – In the short term, today is likely to end relatively strong. While we might see a bit of a pull back tomorrow, it’s not something that I would personally be concerned about. Generally, after massive gains like what we’ve seen, the stock will correct before moving forward with more gains. So, if we see a pull back later today or tomorrow, it’s most likely going to prove to be an opening door to an incredible opportunity as the stock is likely to continue climbing for some time.
  • Long Term – In the long run, I’m also expecting to see bullish activity overall from SGYP. First of Placenatide results were great; and as we all know in biotech, positive study results tend to lead to massive gains. With less chances of a side effect than the leading Linzess, placenatide will likely prove to be an incredibly profitable drug. Also, with strong management and an incredibly talented team of doctors and scientists, I’m expecting to see more positivity from SGYP.

What Do You Think?

Where do you think SGYP is headed and why? Let us know in the comments below!

Image Credit

Big Gainers In Biotech SGYP ZIOP KYTH ARWR

Today is a big day for biotech stocks with many of them in the green. However, there are some that are far outpacing others. I’ve found a few stocks in biotech that are growing rapidly today and may lead to more opportunity down the road. Here they are…

Synergy Pharmaceuticals Climbs On Gastrointestinal Study Results

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

In early morning today, Synergy Pharmaceuticals provided the results for a gastrointestinal study that revolved around placenatide. In the study, patients were given placenatide in a 3 milligram dose; with less than 6% of patients experiencing diarrhea as a side affect. That proved to be far better than what analysts expected and what we saw from Linzess. All in all, investors proved to be incredibly happy about the news. Currently (12:55), SGYP is trading at $7.45 per share after a gain of 60.56%. I’m expecting that following the positive news, we will continue to see growth. So, it may be time to start looking for pull backs that present buying opportunities.

Kythera Biopharmaceuticals Stock Is Up On Acquisition News

Kythera Biopharmaceuticals Inc (NASDAQ: KYTH)

Kythera Biopharmaceuticals stock is having a great day in the market today as well. In the morning, the company announced that it is being acquired by Allergan PLC in a cash and stock deal that works out to be about $75 per share. As a result, the stock climbed. Currently (12:58), KYTH is trading at $74.21 per share after a gain of 13.49% so far today. The value of the stock is still a bit below the value of the acquisition, so there still may be room for profit. If you’re interested, do a bit of research on the acquisition, Allergan stock, and decide if now is the time to get in for gains.

ZIOPHARM Oncology Stock Continues Climbing On High Volume


ZIOPHARM Oncology stock has been climbing all week on high volume, and that trend isn’t slowing down today. Over the past 3 months, ZIOP has had an average daily volume of 3,991,553 according to data from CNN Money. However, today 3,444,650 shares have traded hands so far (1:03). With volume at incredibly high levels for the past 3 days, it’s clear that investors are falling in love with this stock. So, I’m not expecting the positive trend to reverse any time soon. With that said, this may be another one to start looking for pull backs in for great entrance opportunities.

Arrowhead Research Corp Stock Gains On German Clearance

Arrowhead Research Corp (NASDAQ: ARWR)

Finally, Arrowhead Research Corp is another in biotech that’s having a great day in the market today. The growth comes as the company announced that they have received clearance for further HBV testing in Germany. Currently, ARWR is trading at $ per share after a gain of %. With the new news, I’m expecting to see more bullish movement from ARWR moving forward. So, once again, look for dips as possible buying opportunities.

Do You Know Of Any Others?

Do you know of any other biotech stocks that are growing today and likely to continue bullish trends? If so, let us know in the comments below!

Image Credit

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5772
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...